Commercial-stage biopharmaceutical company ADC Therapeutics SA (ADCT) has a clear slate of near-term clinical and operational catalysts that center on ZYNLONTA's development in relapsed or refractory diffuse large B-cell lymphoma and the company's extended financial runway.
The most immediate focus is on additional LOTIS-7 data in the second half of 2025, LOTIS-5 reaching prespecified progression-free survival (PFS) events by year-end, and preparations that position ZYNLONTA for potential advancement across lines of therapy. These events set the stage for data flow and potential regulatory steps through 2026 and beyond.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com